Supplying delivery systems to help prevent cardiovascular disease

Nucleic acid-based therapeutics require sophisticated technologies to deliver the active and overcome challenges such as instability. Croda is the leader in non-viral delivery systems for nucleic acid. We are working on many gene therapy applications including a phase III trial with Verve Therapeutics to cure genetically induced high cholesterol, a condition affecting 31 million people worldwide that can lead to accelerated heart disease and early death. Verve Therapeutics recently dosed the world’s first patient with a gene editing medicine to correct the disorder, using lipids supplied by Croda as the delivery system. In preclinical studies, a single dose of the drug to silence the problematic gene resulted in a 60% reduction in LDL-cholesterol, persisting for 20 months.